Ignite Creation Date:
2025-12-25 @ 12:10 AM
Ignite Modification Date:
2026-02-24 @ 2:30 PM
Study NCT ID:
NCT01108458
Status:
TERMINATED
Last Update Posted:
2017-03-03
First Post:
2010-04-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Sponsor:
George Albert Fisher
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Pancreatic Cancer | View |
Keywords: